Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
33 hedge funds and large institutions have $54.4M invested in Eiger BioPharmaceuticals, Inc. in 2017 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 13 closing their positions.
37% more capital invested
Capital invested by funds: $39.6M → $54.4M (+$14.8M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
15% less funds holding
Funds holding: 39 → 33 (-6)
46% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.23M |
| 2 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
+$727K |
| 3 |
Renaissance Technologies
New York
|
+$505K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$383K |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$282K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.19M |
| 2 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$711K |
| 3 |
HP
Hikari Power
Tokyo,
Japan
|
-$482K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$284K |
| 5 |
Goldman Sachs
New York
|
-$272K |
EIGR Hedge Fund Activity: Q3 2017 in Review
33 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q3 2017, worth a combined $54.4M — up 37% from $39.6M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of EIGR and 7 opened new positions — a net loss of 6 holders — while 7 trimmed existing stakes and 7 added.
The largest buyer was Sphera Funds Management, adding an estimated $1.23M. The largest seller was Sabby Management, cutting an estimated $1.19M.
- 33 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q3 2017, down from 39 in Q2 2017.
- Funds reported $54.4M of Eiger BioPharmaceuticals, Inc. stock for Q3 2017, up 37% quarter-over-quarter.
- 7 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q3 2017 and 13 closed out, a net change of -6 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q3 2017 was Sphera Funds Management, an estimated $1.23M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q3 2017 was Sabby Management, an estimated $1.19M sold.
Based on aggregated 13F filings for Q3 2017.